Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
103
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
3D Medicines
•
02 Dec 2022 11:06
Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation
The overall quality/core competitiveness of 3D Medicines isn't high. Its pipeline is mainly based on license-in model, which is not favored by Mr....
Xinyao (Criss) Wang
Follow
440 Views
Share
bearish
•
Wuxi Biologics
•
27 Nov 2022 09:03
China Healthcare Weekly (Nov25)-Wuxi Biologics, Valuation Logic Changed by NRDL, Biotech Model Fails
NRDL negotiation completely changes the valuation logic of innovative drug. We've some concerns about WuXi Bio's new business updates. The model...
Xinyao (Criss) Wang
Follow
385 Views
Share
bearish
•
Wuxi Biologics
•
11 Oct 2022 08:39
Wuxi Biologics (2269.HK) - Removed from UVL, but the Crisis Is Not Over
Removal from UVL won’t bring fundamental change.The logic of CXO(low labor cost+booming US pharmaceutical IPO) is untenable.We provide trading...
Xinyao (Criss) Wang
Follow
279 Views
Share
bearish
•
Thematic (Sector/Industry)
•
04 Sep 2022 08:56
China Healthcare Weekly(Sep2)-Online Drug Sale, Biotech's Historical Opportunity, Biotech to Be CDMO
New policy of online drug sales is released,including certain restrictions.The rise of China biotech is based on historical opportunity of alpha...
Xinyao (Criss) Wang
Follow
265 Views
Share
bearish
•
Pharmaron Beijing
•
26 Jul 2022 09:04
Pharmaron Beijing Co Ltd (3759.HK/300759.CH) - The Story May Have Changed
Due to overcapacity/fierce competition,Pharmaron is hard to achieve V-shaped rebound by the strategy of "integration".We are conservative about its...
Xinyao (Criss) Wang
Follow
310 Views
Share
First
Previous
7
8
9
10
11
12
13
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.7
x